Posted by Michael Wonder on 01 Oct 2018
PHARMAC must fund breakthrough treatment
1 October 2018 - Cystic Fibrosis NZ and Kalydeco for Kiwis have launched a joint campaign urging PHARMAC to fund the cystic fibrosis treatment Kalydeco.
Kalydeco is a type of medicine used to treat a strand of cystic fibrosis called G551D.
Kalydeco is the first medication that fixes the underlying cystic fibrosis defect, essentially turning off cystic fibrosis. Kalydeco represents a major breakthrough in cystic fibrosis research; current medications only treat the symptoms.
